Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study

Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Daisuke, Yoshino, Takayuki, Kotaka, Masahito, Kawazoe, Akihito, Masuishi, Toshiki, Taniguchi, Hiroya, Yamazaki, Kentaro, Yamanaka, Takeharu, Oki, Eiji, Muro, Kei, Komatsu, Yoshito, Bando, Hideaki, Satake, Hironaga, Kato, Takeshi, Tsuji, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541955/
https://www.ncbi.nlm.nih.gov/pubmed/34019214
http://dx.doi.org/10.1007/s10637-021-01125-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541955/
https://www.ncbi.nlm.nih.gov/pubmed/34019214
http://dx.doi.org/10.1007/s10637-021-01125-2

Ejemplares similares